ATE196314T1 - Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit - Google Patents

Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit

Info

Publication number
ATE196314T1
ATE196314T1 AT97946405T AT97946405T ATE196314T1 AT E196314 T1 ATE196314 T1 AT E196314T1 AT 97946405 T AT97946405 T AT 97946405T AT 97946405 T AT97946405 T AT 97946405T AT E196314 T1 ATE196314 T1 AT E196314T1
Authority
AT
Austria
Prior art keywords
compositions
methods
angiogenesis
alpha subunit
preventing inflammation
Prior art date
Application number
AT97946405T
Other languages
English (en)
Inventor
Kathleen Kelly
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE196314T1 publication Critical patent/ATE196314T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97946405T 1996-10-25 1997-10-24 Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit ATE196314T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2787196P 1996-10-25 1996-10-25
PCT/US1997/019772 WO1998017796A2 (en) 1996-10-25 1997-10-24 Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit

Publications (1)

Publication Number Publication Date
ATE196314T1 true ATE196314T1 (de) 2000-09-15

Family

ID=21840250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946405T ATE196314T1 (de) 1996-10-25 1997-10-24 Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit

Country Status (8)

Country Link
US (2) US6365712B1 (de)
EP (1) EP0938557B1 (de)
JP (1) JP2001510987A (de)
AT (1) ATE196314T1 (de)
AU (1) AU5158098A (de)
CA (1) CA2270154A1 (de)
DE (1) DE69703121D1 (de)
WO (1) WO1998017796A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009188A1 (en) * 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
EP1263484B1 (de) 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Beschichtung welche ein anhaften von endothelzellen stimuliert
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
GB0009181D0 (en) * 2000-04-13 2000-05-31 Isis Innovation Protein
GB2367822A (en) * 2000-06-19 2002-04-17 Smithkline Beecham Corp CD97 polypeptides
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
AU2002252175A1 (en) 2001-03-02 2002-09-19 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2003062438A1 (en) * 2002-01-22 2003-07-31 Biomatera Inc. Method of drying biodegradable polymers
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US7727718B2 (en) * 2005-01-04 2010-06-01 Molecular Research Center, Inc. Reagents for storage and preparation of samples for DNA analysis
EP1981338A2 (de) * 2006-01-13 2008-10-22 Advanced Bionutrition Corporation Produktionssystem mit kontinuierlicher sprühnebelaufnahme
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
WO2011102394A1 (ja) 2010-02-17 2011-08-25 日本たばこ産業株式会社 植物内容成分の調節因子、およびその利用
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP3193915A1 (de) 2014-07-21 2017-07-26 Novartis AG Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (de) 2015-04-23 2018-02-28 Novartis AG Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN108603200B (zh) 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
CN109072195A (zh) 2015-12-30 2018-12-21 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
CN110267677A (zh) 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP3574005B1 (de) 2017-01-26 2021-12-15 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
EP3577134A1 (de) 2017-01-31 2019-12-11 Novartis AG Behandlung von krebs mit chimären t-zellrezeptorproteinen mit mehreren spezifitäten
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (de) 2018-05-01 2021-03-10 Novartis Ag Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
EP3801769A1 (de) 2018-05-25 2021-04-14 Novartis AG Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
EP3959320A1 (de) 2019-04-24 2022-03-02 Novartis AG Zusammensetzungen und verfahren für selektiven proteinabbau
CN110627903B (zh) * 2019-10-29 2021-09-21 河南大学 抗cd97单克隆抗体、其可变区与恒定区序列及应用
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
TW202500126A (zh) 2023-05-24 2025-01-01 美商金橘生物科技公司 雜環化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328968B1 (en) * 1996-08-09 2001-12-11 Stichting Sanquin Bloedvoorziening Methods and means for modifying complement activation

Also Published As

Publication number Publication date
DE69703121D1 (de) 2000-10-19
US6846911B2 (en) 2005-01-25
US20020168361A1 (en) 2002-11-14
US6365712B1 (en) 2002-04-02
EP0938557B1 (de) 2000-09-13
JP2001510987A (ja) 2001-08-07
WO1998017796A2 (en) 1998-04-30
WO1998017796A3 (en) 1998-07-09
CA2270154A1 (en) 1998-04-30
EP0938557A2 (de) 1999-09-01
AU5158098A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DE60039752D1 (de) Herstellung tetravalenter antikörper
TR200000913T2 (tr) Tıbbi maddeler
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
ATE458053T1 (de) Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
TR200000015T2 (tr) Bileşikler ve metodlar
ATE208819T1 (de) Löslicher t-zell rezeptor
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
BR9707819A (pt) Imunogenos peptidicos
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
ATE337399T1 (de) Zusammensetzungen zur immuntherapie und diagnose von tuberculosis
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
EE9900146A (et) Lahustuvad lümfotoksiin-ß retseptorid, lümfotoksiini retseptori vastased antikehad ja lümfotoksiini ligandi vastased antikehad terapeutiliste agensitena immunoloogiliste haiguste raviks
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
EP1762620A3 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
ATE316577T1 (de) Das goodpasture-antigen bindende protein
NZ515382A (en) OX2 receptor homologs
EA200001127A1 (ru) Бактериальные феромоны и их использование
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
NO984522D0 (no) Monoklonale antistoffer som binder humant veksthormon (hGH)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties